Table 2 Anticoagulation of patients with recorded bleedings during PCI
From: Arterial access-site complications after use of a vascular closure device related to puncture height
All patients (n = 50) | Common femoral artery (n = 24) | Femoral bifurcation (n = 15) | Low puncture (n = 11) | p value | |
|---|---|---|---|---|---|
Pre-PCI, n (%) | |||||
ASS | 27 (54) | 11 (46) | 10 (67) | 6 (55) | 0.447 |
Clopiogrel | 9 (18) | 5 (21) | 1 (7) | 3 (27) | 0.346 |
Ticagrelor | 1 (2) | 0 (0) | 1 (7) | 0 (0) | 0.520 |
Prasugrel | 5 (10) | 1 (4) | 3 (20) | 1 (9) | 0.284 |
LMH | 2 (4) | 0 (0) | 1 (6) | 1 (9) | 0.265 |
NOAC/OAC | 8 (16) | 4 (17) | 3 (20) | 1 (9) | 0.886 |
None | 17 (34) | 11 (46) | 2 (13) | 4 (36) | 0.104 |
INR, mean ± SD | 1.07 ± 0.23 | 1.09 ± 0.26 | 1 ± 0.08 | 1.16 ± 0.33 | 0.066 |
Peri-PCI, n (%) | |||||
Heparin | 50 (100) | 24 (100) | 15 (100) | 11 (100) | 1 |
GP IIB/IIIA inhibitor | 2 (4) | 1 (4) | 0 (0) | 1 (9) | 0.481 |
Bivalirudin | 1 (2) | 0 (0) | 1 (7) | 0 (0) | 0.520 |
Post-PCI, n (%) | |||||
ASS + Clopidogrel | 33 (66) | 14 (58) | 10 (67) | 9 (82) | 0.395 |
ASS + Ticagrelor | 4 (8) | 1 (4) | 2 (13) | 1 (9) | 0.545 |
ASS + Presugrel | 6 (12) | 5 (21) | 1 (7) | 0 (0) | 0.279 |
ASS + NOAC/OAC | 0 (0) | 0 (0) | 0 (0) | 0 (0) | - |
Thienopyridine + NOAC/OAC | 3 (6) | 1 (4) | 2 (13) | 0 (0) | 0.432 |
Triple Therapy | 4 (8) | 3 (13) | 0 (0) | 1 (9) | 0.424 |